PubMed Health⌕ Search

Biomedical subjects

E N Sholokhova

Publications and source records attributed to E N Sholokhova.

At least 19 recordsLinked to original sources
PubMed2006

[MALT-lymphomas in Sjogren's disease].

AIM: To develop algorithm of early diagnosis of extranodal lymphoma arising in patients with Sjorgen's disease (SD). MATERIAL AND METHODS: SD diagnosis was made in 457 patients treated in Rheumatology Institute clinic in 1999-2004, 38 (8.3%) females aged 19-82 had lymphoproliferative diseases. MALT-lymphomas were diagnosed in 15 (42.2%) patients. All the patients have undergone morphological, immunomorphological investigations of the salivary glands, postoperative material was analysed in some patients. In addition, the following investigations were made: ultrasonography of the salivary glands, lymph nodes, viscera; scintigraphy; trephine biopsy of the bone marrow; myelograms; CT of the chest, abdomena and brain; tests for monoclonal immunoglobulins in the serum and light chains in urine; biopsy of the parotid gland. Clinical, morphological and immunophenotypical characteristics of MALT-lymphomas were assessed by WHO classification. Lymphoma stages were classified according to Ann Arbor. RESULTS: Parotid glands were affected with MALT-lymphoma most frequently. Predominant were extranodal lymphomas of the parotid submandibular, minor salivary glands of the lip and lacrimal glands of stage I E-II E. Extranodal lymphoma with nodal lesion of stage IV occurred less frequently. Untreated long existing MALT-lymphomas of the parotid glands may transform into B-large cell lymphomas deteriorating SD prognosis. The presence of long-term (> 12 months) massive enlargement of parotid/submandibular salivary and lacrimal glands, massive infiltration, monoclonal immunoglobulins in blood serum and their light chains in the urine predict development of MALT-lymphoma in SD. CONCLUSION: In SD, MALT-lymphomas develop primarily in target organs--salivary and lacrimal glands. SD patients with persistent enlargement of the parotid glands need biopsy for early detection of malignant lymphoproliferation.

Adult↗
PubMed2002

[Clinico-immunological characteristics of lymphoid tumors in children].

The clinical and immunological characteristics of lymphoid tumors were compared in 591 children with acute lymphoblastic leukemia (ALL) and non-Hodgkin's lymphoma (NHL). Comprehensive investigation of a tumor cell by using cytological, morphological, and immunological studies revealed the most significant criteria for differential diagnosis of ALL and NHL in children and showed the specific features of the site of a tumor and the extent of its growth in ALL and NHL in relation to the immunological affiliation of a tumor cell. The predominance of immature forms, such as stem-cell CD34+, pre-pre-B, pre-B and less commonly T-cell forms with almost none peripheral B- and T-cell markers could be immunophenotypically detected in ALL. NHL was, on the contrary, characterized by the prevalence of mature immunological subtypes with peripheral B- and T-cell markers and much less frequently pre-B and pre-T cells and at the same time there was no CD34 antigen in the tumor cells. Anaplastic giant lymphoma was a peculiar type of NHL characterized by the presence of large cells having marked anaplasia and expression on the surface of CD30 antigen. A comprehensive study of lymphoid tumors in children showed that immunophenotyping was of great value, whose results were associated with the specific feature of tumor growth and prognosis, which should be borne in mind while planning antitumor therapy programmes.

Adolescent↗
PubMed1999

[Richter's syndrome: analysis of literature data and original observations].

AIM: Review of literature data and original experience with Richter's syndrome. MATERIALS AND METHODS: 250 patients suffering from malignant lymphoproliferative diseases with blood and bone marrow lymphocytosis were observed. 8 (3.2%) of them developed diffuse large-cell lymphoma (criteria and classification of REAL). RESULTS: 5 of the above 8 patients demonstrated spontaneous regression of lymphocytosis. These cases may illustrate transformation (clonal progression) of one morphological variant of malignant non-Hodgkin's lymphoma into another one, more aggressive. For this rare variant of Richter's syndrome running with regression of lymphocytosis the term Richter-Lortolary syndrome is proposed. Lortolary was the first who revealed a decrease of lymphocytosis in Richter's syndrome. The studies of the genome structure, first of all, of immunoglobulin genes show that in Richter-Lortolary syndrome it is easier, to confirm monoclonality of the two tumors (lymphocytic and large-cell) than to reject it. However, the idea of transformation has not been confirmed morphologically yet. CONCLUSION: Development of diffuse large-cell lymphoma in the course of chronic lymphatic tumor does not always indicate terminal state, later stage of tumor progression and poor prognosis.

Female↗
PubMed1996

Reactivity of anti-macrophage monoclonal antibody D11 in human leukemia and malignant lymphoma.

We have studied the reactivity patterns of a previously described pan-macrophage monoclonal antibody (MAb) D11 in 324 cases of acute leukemia and malignant lymphoma (ML). Reaction of D11 in tissue sections was restricted to histiocytes and macrophages. In non-Hodgkin's ML, D11 helped to confirm or to establish the histiocytic nature in 8 of 96 cases, i.e., in 4 of 6 histiocytic MLs; 2 of 13 anaplastic large-cell lymphomas; 1 of 4 large-cell immunoblastic clear-cell MLs; and 1 of 2 histiocytosis X cases. Positive reaction of D11 in acute lymphoblastic leukaemia (ALL) was found in 9 of 86 cases (all belonging to early B-lineage leukemia), of which 4 were CD34-positive and 5 co-expressed 1 or more myeloid/monocytic antigens. MAb D11 did not react in 42 cases of acute-myeloblastic-leukemia (AML) FAB variants M0-M5, except 1 acute mixed-lineage leukemia M1/pre-pre-B. Comparative study of the MAb D11 and a standard CD68 MAb KP- 1 showed that the antigens belong to different epitopes of different molecules.

Acute Disease↗
PubMed1996

[The prolymphocytic-lymphocytic leukemization of B-cell lymphosarcomas].

The paper presents clinical, hematological, morphological and immunological characteristics of B-cell lymphosarcoma with prolymphocytic-lymphocytic type of leukemization in 50 adult patients (9 females and 41 males aged 29-86 years). In B-cell immunological subvariant of prolymphocytic-lymphocytic leukemization changes in the primary tumor always corresponded to prolymphocytic variant of lymphosarcoma. This distinguishes B-cell lymphosarcomas from previously described T-cellular ones in which the type of eventual leukemic changes did not always correspond to the kind of initial tumor. The presence or absence of prolymphocytes with split nuclei in bone marrow puncture samples was neither of clinical nor of prognostic significance. In leukemization of B-cell prolymphocytic lymphosarcoma from the cells with split nuclei or cells with different configuration of the nuclei, immunological phenotype typical for B-cell chronic lymphoid leukemia did not occur. In prolymphocytic lymphosarcoma from cells with round nuclei one-third of patients had immunological phenotype more typical for B-cell chronic lymphoid leukemia. However, among them were patients with aggressive course with predominant extranodal location of tumor and prolymphocytic type of leukemization. Tumor nodes in B-cell prolymphocytic lymphosarcomas, irrespective of leukemization morphological variant, proved rather resistant to therapy. A complete clinicohematological remission according to the international criteria occurred in 2 of 50 patients, only.

Adult↗
PubMed1995

[The prolymphocytic-lymphocytic leukemization of T-cell lymphosarcomas].

The paper presents a detailed clinical, hematological, morphological, ultrastructural and immunological characterisation of T-cell lymphosarcoma with prolymphocytic-lymphocytic leukemic transformation (PLLT). In PLLT the proportion of T-cell immunological subvariant of lymphosarcoma came to 15% being detected only in 8 out of 52 examinees. The patients (6 males and 2 females) varied in age from 24 to 76 years (median 49 years) and had the following histological forms of primary tumor tissue: lymphoblastic lymphosarcoma (n = 3), pleiomorphic small cell lymphosarcoma (n = 1), large-cell anaplastic lymphosarcoma (n = 1), prolymphocytic lymphosarcoma. Immunological characteristics of these 8 cases were heterogeneous: in lymphoblastic variant there was immature T-immunological phenotype. In pleomorphic small-cell lymphosarcoma there were also signs of T-cell activation. In large-cell anaplastic lymphosarcoma an immunological phenotype of lymphoid cells from the primary tumor tissue and bone marrow differed in more advanced immunological differentiation of bone marrow tumor cells. In prolymphocytic variant tumor cells had features of T-helpers or T-suppressors. Most of the patients received polychemotherapy according to the schemes for high-grade lymphosarcomas despite PLLT though the latter is not a universal indicator of late tumor progression, more aggressive course of the disease and poor prognosis.

Adult↗
PubMed1994

[The clinicoimmunological characteristics of blast transformation in lymphosarcomas].

The authors studied a blast cell immunological phenotype in 50 adults with lymphosarcoma undergoing leukemization following the pattern of acute leukemia. Among the patients there were 12 females and 38 males aged 14-61. Immunological phenotyping of tumor cells was performed using a panel of monoclonal antibodies to T- and B-lymphocyte antigens, to myelomonocytic cells, some nonlinear and activation antigens. T, B and zero variants of blast cells were identified. Occasionally, blast cells carried nonlymphoid antigens and those corresponding to the common lymphosarcoma subvariant. Leukemization in the direction of lymphoblastic leukemia is associated with greater frequency of lymphosarcoma T subvariant (46%). B-cell and zero subvariants occurred in 28% and 20% of the patients, respectively. The number of complete remissions in the group of patients with T-cell subvariant was greater than in the group with B-cell subvariant. The survival in these two groups, however, was almost similar (median up to 8-12 months). Further studies into lymphoblastic leukemization immunophenotyping can help design programs of differentiated polychemotherapy.

Adolescent↗
PubMed1992

[Epithelial membrane antigen in lymphosarcoma cells (immunomorphologic study)].

11 cases of different types of lymphosarcoma of T- and B-nature are studied immunohistochemically by means of antibodies against epithelial membrane antigen (EMA), including new Soviet monoclonal antibodies ICO-25 to this antigen, common leucocytic antigen, vimentin and cytokeratin. The phenomenon of the EMA including ICO-25 binding to the cells of some lymphosarcomas is confirmed. This indicates that the use of only this "epithelial differentiation marker" in not sufficient for the differentiation between lymphosarcoma and poorly differentiated carcinoma. Variability of lymphosarcoma cells staining by vimentin antibodies is shown, other limitations of the immunohistochemical examination of lymphoma are discussed. The conclusion is made of the necessity to use the spectrum of the above antibodies when differentiating between lymphosarcoma and poorly differentiated carcinoma.

Antigens, Differentiation↗
PubMed1990

[Immunologic prognosis in hemoblastoses in children].

The diagnostic value of monoclonal antibodies is discussed. The expression of ICO-GM1 and ICO-G2 myeloid antigens in pediatric patients with nonlymphoblastic leukemia was associated with poor prognosis whereas patients with the expression of T-cell markers fared better. The prognostic value of the antigens was not altered by brief cytotoxic treatment. The prognosis for non-T-cell ICO-II+ type childhood lymphosarcoma was worse as compared to Ia+ICO-II- lymphoma subset. It was concluded that the biology of malignant cells and degree of cell differentiation (as assessed immunologically) affects treatment outcome significantly and should be considered in individualizing therapy for childhood lymphosarcoma and leukemia.

Antibodies, Monoclonal↗
PubMed1989

[Monoclonal antibodies in the study of malignant skin lymphomas].

Comprehensive analysis of skin infiltrate cells, carried out in malignant lymphomas of the skin, has included examinations with the use of monoclonal antibodies (MCA). Basing on the clinical, histologic, and immunologic findings, mycosis fungoides has been diagnosed in 9 patients and T-cellular lymphoblastic lymphosarcoma consisting of T-suppressors in 1. The findings evidence that (1) mycosis fungoides is a tumor consisting of OKT4 cells in the majority of cases; (2) mature T-cell markers are sometimes lost in the course of mycosis fungoides, this being parallelled by the emergence of antigens characteristic of earlier differentiation stages, e. g. corticothymocytic ones; (3) immunologic heterogeneity is a characteristic feature of malignant lymphomas of the skin; this may be explained by both: the tumor progress of the clone and the therapeutic pathomorphosis; (4) use of MCA to a wide spectrum of leukocytic differentiation antigens permits an accurate estimation of the nature of the tumor cells and of the cellular relationships; this helps understand the pathogenesis of malignant lymphomas of the skin and develop new treatment modalities.

Antibodies, Monoclonal↗
PubMed1989

[The immunology of CD4-negative skin hematosarcomas].

A wide panel of monoclonal antibodies to hematopoietic cell differentiation antigens was applied to the study of CD4-negative skin hematosarcomas on cryostat secretions. The most frequent CD4-negative type was the B-cell one identified in 6 of 10 cases. In this type the use of monoclonal antibodies in addition to standard immunoglobulin markers seemed to be very important. T-cell type (CD3+ CD8+), histiocytic variant (CD11+Ia+), pseudolymphoma (polyclonal markers pattern), and Kaposi's sarcoma (hematopoietic cell negative antigen) were identified in 1 case each. The authors emphasize the importance of immunological studies of hematosarcomas because of the high frequency of the generalization of B-cell lymphomas; such studies may also help in the differential diagnosis between pseudolymphoma and hematosarcoma.

Adolescent↗
PubMed1988

[Monoclonal antibodies ICO-20 against human thymocyte antigen T10].

Monoclonal antibodies (Mab) Ig G2a isotypes reacting in indirect immunofluorescence assay with 68.7 +/- 4.1% of thymocytes, 7% of T-cells and not determining the antigen on other blood cells were obtained. Mab ICO-20 reacted in complement-dependent cytotoxic test. The antigen was expressed on colony-forming cells of granulocyte-macrophage row. Mab ICO-20 reaction with 100% of thymocytes was defined by flow cytometry. Antigen molecular mass is 45000 Dalton. The antigen was expressed on blast cells of patients with ALL and AML. Mab ICO-20 reaction was more more often with T-cell ALL.

ADP-ribosyl Cyclase↗
PubMedDate not supplied

[Dipeptidyl aminopeptidase-IV as a histochemical marker of differential diagnosis of large cell anaplastic CD30+-lymphoma and Hodgkin's disease].

Using histochemical methods, we studied distribution of dipeptidylaminopeptidase-IV (DPP-IV) in tumor cells of 16 patients with non-Hodgkin's malignant lymphomas (NHL) including B-cell NHL (10 cases), pleomorphic T-cell lymphoma (1 case), CD30+ anaplastic large cell lymphoma (ALCL) of T-cell (1 case) and ALCL of null-cell type (4 cases) and of 13 patients with Hodgkin's disease (HD). The results indicate that tumour cells of pleomorphic T-cell NHL and ALCL of T- and null-cell type showed DPP-IV activity. In contrast, no DPP-IV activity was seen in the tumor cells of B-cell NHL (lymphocytic, centroblastic/centrocytic, centroblastic, immunoblastic), in Berezovsky-Reed-Sternberg and Hodgkin's cells of different HD variants. These results demonstrate that difference in DPP-IV activity between tumor cells of ALCL and HD may be diagnostically important for separation of ALCL from HD and moreover may be used in verification of the borderline between HD-like ALCL and ALCL-like HD. It is possible that DPP-IV activity contributes to pathogenesis of ALCL and may determine clinical behaviour of this NHL being involved in autocrine and paracrine regulation of tumor cell growth of ALCL.

Biomarkers, Tumor↗
PubMedDate not supplied

[Differential diagnosis of B-cell lymphoma rich in T cells and peripheral T-cell lymphomas].

Clinicomorphological analysis of T-cell-rich B-cell lymphoma in a 50-year-old female and literature data revealed objective difficulties in morphological diagnosis using cytological and histological methods. Large number of epithelioid histiocytes and tumor cells polymorphism resembled Lennert's lymphoma (peripheral T-cell lymphoma). Immunohistochemical study confirmed B-cell origin of tumor cells and large number of reactive T-cells. It is suggested that it would be more correctly to use the term "Lennert-like areas" in such cases with subsequent immunohistochemical study.

Diagnosis, Differential↗
PubMedDate not supplied

[Cytomorphological differentiation diagnosis and evaluation of p53mut, bcl-2, CD95 in peripheral B-cell small cell lymphomas].

Basing on the analysis of the cytological evidence, the authors suggest criteria for differential diagnosis of peripheral small-cell B-cell lymphomas including position of the tumor cells in cytological preparations and cell composition of the tumor. A high level of p53mut and bcl-2 expression in centrofollicular lymphomas and lymphomas originating from small lymphocytes may serve an additional criterion in differential diagnosis with reactive changes in the lymph nodes.

Biomarkers, Tumor↗